Eton Pharmaceuticals, Inc. (ETON): Revenue
$79.95M
Year ended 2025-12-31
$105.59M
Trailing 12 months to 2026-06-30
+55.5%
3-year compound annual growth
n/m
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $79.95M | +104.9% | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | $39.01M | +23.3% | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | $31.64M | +48.9% | 2026-03-19, From 2023-01-01 |
| 2022-12-31 | $21.25M | -2.7% | 2025-03-18, From 2022-01-01 |
| 2021-12-31 | $21.83M | n/m | 2024-03-14, From 2021-01-01 |
| 2020-12-31 | $39.0K | -95.9% | 2023-03-16, From 2020-01-01 |
| 2019-12-31 | $959.0K | n/a | 2022-03-16, From 2019-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $79.95M | +104.9% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $81.36M | +14.9% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $82.03M | -46.1% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $76.20M | -44.8% |
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $83.98M | +54.0% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $84.28M | -5.5% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $75.13M | +160.6% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $85.33M | -6.2% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $88.04M | +376.6% |
Compare ETON, ADCT, ARCT, CTMX side by side · Screen every company in Pharmaceutical Preparations ↗